BigBio provides biotech companies and investors with rapid, source‑verified analyses of critical data—such as grant details, regulatory filings, and clinical readouts—delivered in days instead of months. By tracing every figure to its original filing, trial registry, or peer‑reviewed paper, the platform ensures decisions are based on verifiable information, reducing the risk of costly misinterpretations in R&D, regulatory, and investment workflows.
Funding
Funding not disclosed
Founders
Product
Problem
Biotech investors and operators often base decisions on incomplete or unverified data hidden in regulatory filings, trial registries, and scientific papers, leading to costly misreads across R&D, clinical, regulatory, and commercial stages.
Solution
BigBio provides rapid, source‑verified decision intelligence that extracts and consolidates data from filings, trial registries, and peer‑reviewed literature into concise reports delivered in days. Each claim is linked to its original DOI, PMID, NCT, or CIK identifier and includes a retrieval timestamp, enabling users to re‑verify any figure independently. An AI‑driven audit model checks every assertion against the source lineage, flagging inconsistencies without introducing new information. The platform pre‑registers its analyses, making the timing of each call auditable. This workflow turns scattered public information into a capital‑ready narrative for founders and a validated asset read for investors before a deal is made.
Target Audience
Primary customers are biotech founders seeking validated, capital‑ready narratives and investors or corporate development teams requiring source‑verified diligence on assets, pipelines, or market opportunities.
Features
- Automatic extraction of quantitative data from regulatory filings, trial registries, and peer‑reviewed papers
- Full traceability of every data point to a durable identifier (DOI, PMID, NCT, CIK) with a retrieval timestamp
- AI audit engine that validates claims against source lineage and raises only false‑positive alerts
- Pre‑registration of analysis calls to create an immutable audit trail of predictions versus outcomes
- Concise, investor‑focused reports delivered within ~10 business days for a fixed scope
- Customizable diligence engagements for deeper mechanism audits, catalyst reads, or full data‑room analyses